Maillard Nicolas, Perrotton Fanny, Delage Emilie, Gourraud Jean-Baptiste, Lande Gilles, Solnon Aude, Probst Vincent, Grimandi Gael, Clouet Johann
Pharmacy Department, PHU7, Nantes University Hospital, Nantes, France.
Cardiology Department, PHU2, Nantes University Hospital, Saint Herblain, France.
Arch Cardiovasc Dis. 2014 Apr;107(4):253-60. doi: 10.1016/j.acvd.2014.02.004. Epub 2014 Apr 4.
The increase in number of implanted cardiac medical devices and the announced decrease in number of cardiologists have led to remote monitoring being considered as a pivotal tool for patient follow-up. For 10 years, remote monitoring has been the subject of multiple clinical studies. In these studies, reliability and clinical efficacy have been demonstrated, but the use of remote monitoring remains quite limited in France compared with other countries. To explain this delay in uptake, some organizational difficulties and the lack of reimbursement of remote monitoring are often mentioned. The results of medico-economic studies might provide answers about the value of remote monitoring and enable the supervisory authorities to define how its use will be financed. This review provides a global view of remote monitoring in France, and covers the principle, clinical efficacy, organizational and regulatory aspects, and medico-economic data.
植入式心脏医疗设备数量的增加以及已公布的心脏病专家数量的减少，使得远程监测被视为患者随访的关键工具。十年来，远程监测一直是多项临床研究的主题。在这些研究中，其可靠性和临床疗效已得到证实，但与其他国家相比，法国对远程监测的使用仍然相当有限。为了解释这种采用延迟的情况，人们经常提到一些组织方面的困难以及远程监测缺乏报销。药物经济学研究的结果可能会为远程监测的价值提供答案，并使监管机构能够确定其使用的资金来源。本综述提供了法国远程监测的全景，涵盖了原理、临床疗效、组织和监管方面以及药物经济学数据。
